Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BMS-986036 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

NCT03445208
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

NCT03486899
View directory record Official record
Conditions
Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
83
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

NCT04634149
View directory record Official record
Conditions
Moderate Liver Impairment, Severe Liver Impairment
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

NCT03198182
View directory record Official record
Conditions
Metabolics
Interventions
Placebo, BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03400163
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

NCT04493567
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

NCT02097277
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
BMS-986036, Placebo (Matching with BMS-986036)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Anaheim, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 20, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT02413372
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Rialto, California • San Diego, California • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 20, 2026, 5:37 AM EDT
Completed No phase listed Interventional Results available

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

NCT03611101
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device
Combination Product · Drug · Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Humble, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 20, 2026, 5:37 AM EDT